FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1023-1035 March 4, 2004 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The use of combinations of antiretroviral drugs has proven remarkably effective in controlling the progression of human immunodeficiency virus (HIV) disease and prolonging survival,¹ but these benefits can be compromised by the development of drug resistance.^2,3 Resistance is the consequence of mutations that emerge in the viral proteins targeted by antiretroviral agents. In the United States, as many as 50 percent of patients receiving antiretroviral therapy are infected with viruses that express resistance to at least one of the available antiretroviral drugs.⁴ Consequently, the transmission of drug-resistant strains is also a growing concern.^5,6,7 Because drug-resistant HIV often exhibits resistance to . . . [Full Text of this Article]

Principles of Drug Therapy for HIV

Development of Resistance

Induced Resistance

Primary Resistance

Mechanisms of Resistance

Resistance to Nucleoside and Nucleotide Analogues

            Impairment of Analogue Incorporation

            Removal of the Analogue from the Terminated DNA Chain

Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors

Resistance to Protease Inhibitors

Resistance to Fusion Inhibitors

Cross-Resistance

Evolution of Resistance

Effect of Resistance on Viral Replicative and Pathogenic Capacity

Minority and Archived Populations of Virus

Testing for Drug Resistance

Perspectives

Source Information

From the Unité de Recherche Antivirale, Institut National de la Santé et de la Recherche Médicale, Unité 552, Hôpital Bichat–Claude Bernard, Paris.

Address reprint requests to Dr. Clavel at INSERM, U552, IMEA, Hôpital Bichat–Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France, or at clavel@bichat.inserm.fr.

Related Letters:

HIV Drug Resistance
Calmy A., Pascual F., Ford N.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:2720-2721, Jun 24, 2004. Correspondence

This article has been cited by other articles:

• Rey, D., Hoen, B., Chavanet, P., Schmitt, M. P., Hoizey, G., Meyer, P., Peytavin, G., Spire, B., Allavena, C., Diemer, M., May, T., Schmit, J. L., Duong, M., Calvez, V., Lang, J. M. (2008). High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 0: dkn471v1-9 [Abstract] [Full Text]  
• Goethals, O., Clayton, R., Van Ginderen, M., Vereycken, I., Wagemans, E., Geluykens, P., Dockx, K., Strijbos, R., Smits, V., Vos, A., Meersseman, G., Jochmans, D., Vermeire, K., Schols, D., Hallenberger, S., Hertogs, K. (2008). Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors. J. Virol. 82: 10366-10374 [Abstract] [Full Text]  
• Vijay, N. N. V., Vasantika, , Ajmani, R., Perelson, A. S., Dixit, N. M. (2008). Recombination increases human immunodeficiency virus fitness, but not necessarily diversity. J. Gen. Virol. 89: 1467-1477 [Abstract] [Full Text]  
• Shimura, K., Kodama, E., Sakagami, Y., Matsuzaki, Y., Watanabe, W., Yamataka, K., Watanabe, Y., Ohata, Y., Doi, S., Sato, M., Kano, M., Ikeda, S., Matsuoka, M. (2008). Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137). J. Virol. 82: 764-774 [Abstract] [Full Text]  
• Ceccherini-Silberstein, F., Svicher, V., Sing, T., Artese, A., Santoro, M. M., Forbici, F., Bertoli, A., Alcaro, S., Palamara, G., d'Arminio Monforte, A., Balzarini, J., Antinori, A., Lengauer, T., Perno, C. F. (2007). Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors. J. Virol. 81: 11507-11519 [Abstract] [Full Text]  
• Detsika, M. G., Chandler, B., Khoo, S. H., Winstanley, C., Cane, P., Back, D. J., Owen, A. (2007). Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. J Antimicrob Chemother 60: 881-884 [Abstract] [Full Text]  
• Hoffmann, C., Minkah, N., Leipzig, J., Wang, G., Arens, M. Q., Tebas, P., Bushman, F. D. (2007). DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res 35: e91-e91 [Abstract] [Full Text]  
• Chinnadurai, R., Rajan, D., Munch, J., Kirchhoff, F. (2007). Human Immunodeficiency Virus Type 1 Variants Resistant to First- and Second-Version Fusion Inhibitors and Cytopathic in Ex Vivo Human Lymphoid Tissue. J. Virol. 81: 6563-6572 [Abstract] [Full Text]  
• Perez-Bercoff, D., Wurtzer, S., Compain, S., Benech, H., Clavel, F. (2007). Human Immunodeficiency Virus Type 1: Resistance to Nucleoside Analogues and Replicative Capacity in Primary Human Macrophages. J. Virol. 81: 4540-4550 [Abstract] [Full Text]  
• Davaro, R. E., Thirumalai, A. (2007). Life-Threatening Complications of HIV Infection. J Intensive Care Med 22: 73-81 [Abstract]  
• Beerenwinkel, N., Drton, M. (2007). A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data. Biostatistics 8: 53-71 [Abstract] [Full Text]  
• Espinoza, L., Hall, H. I., Hardnett, F., Selik, R. M., Ling, Q., Lee, L. M. (2007). Characteristics of Persons With Heterosexually Acquired HIV Infection, United States 1999-2004. Am. J. Public Health 97: 144-149 [Abstract] [Full Text]  
• Jochmans, D., Deval, J., Kesteleyn, B., Van Marck, H., Bettens, E., De Baere, I., Dehertogh, P., Ivens, T., Van Ginderen, M., Van Schoubroeck, B., Ehteshami, M., Wigerinck, P., Gotte, M., Hertogs, K. (2006). Indolopyridones Inhibit Human Immunodeficiency Virus Reverse Transcriptase with a Novel Mechanism of Action. J. Virol. 80: 12283-12292 [Abstract] [Full Text]  
• The Strategies for Management of Antiretroviral Th, (2006). CD4+ Count-Guided Interruption of Antiretroviral Treatment. NEJM 355: 2283-2296 [Abstract] [Full Text]  
• Aquaro, S., Svicher, V., Schols, D., Pollicita, M., Antinori, A., Balzarini, J., Perno, C. F. (2006). Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. J. Leukoc. Biol. 80: 1103-1110 [Abstract] [Full Text]  
• Labrosse, B., Morand-Joubert, L., Goubard, A., Rochas, S., Labernardiere, J.-L., Pacanowski, J., Meynard, J.-L., Hance, A. J., Clavel, F., Mammano, F. (2006). Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.. J. Virol. 80: 8807-8819 [Abstract] [Full Text]  
• Solomon, S, Solomon, S S, Ganesh, A K (2006). AIDS in India.. Postgrad. Med. J. 82: 545-547 [Full Text]  
• Gulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lalama, C., Schackman, B. R., Meyer, W. A. III, Acosta, E. P., Schouten, J., Squires, K. E., Pilcher, C. D., Murphy, R. L., Koletar, S. L., Carlson, M., Reichman, R. C., Bastow, B., Klingman, K. L., Kuritzkes, D. R., for the AIDS Clinical Trials Group (ACTG) A5095 St, (2006). Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.. JAMA 296: 769-781 [Abstract] [Full Text]  
• Svicher, V., Sing, T., Santoro, M. M., Forbici, F., Rodriguez-Barrios, F., Bertoli, A., Beerenwinkel, N., Bellocchi, M. C., Gago, F., d'Arminio Monforte, A., Antinori, A., Lengauer, T., Ceccherini-Silberstein, F., Perno, C. F. (2006). Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors. J. Virol. 80: 7186-7198 [Abstract] [Full Text]  
• Deeks, S. G (2006). Antiretroviral treatment of HIV infected adults.. BMJ 332: 1489-1489 [Full Text]  
• Pallier, C., Castera, L., Soulier, A., Hezode, C., Nordmann, P., Dhumeaux, D., Pawlotsky, J.-M. (2006). Dynamics of Hepatitis B Virus Resistance to Lamivudine. J. Virol. 80: 643-653 [Abstract] [Full Text]  
• Wurtzer, S., Compain, S., Benech, H., Hance, A. J., Clavel, F. (2005). Effect of Cell Cycle Arrest on the Activity of Nucleoside Analogues against Human Immunodeficiency Virus Type 1. J. Virol. 79: 14815-14821 [Abstract] [Full Text]  
• Beerenwinkel, N., Sing, T., Lengauer, T., Rahnenfuhrer, J., Roomp, K., Savenkov, I., Fischer, R., Hoffmann, D., Selbig, J., Korn, K., Walter, H., Berg, T., Braun, P., Fatkenheuer, G., Oette, M., Rockstroh, J., Kupfer, B., Kaiser, R., Daumer, M. (2005). Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 21: 3943-3950 [Abstract] [Full Text]  
• Cigler, P., Kozisek, M., Rezacova, P., Brynda, J., Otwinowski, Z., Pokorna, J., Plesek, J., Gruner, B., Doleckova-Maresova, L., Masa, M., Sedlacek, J., Bodem, J., Krausslich, H.-G., Kral, V., Konvalinka, J. (2005). From nonpeptide toward noncarbon protease inhibitors: Metallacarboranes as specific and potent inhibitors of HIV protease. Proc. Natl. Acad. Sci. USA 102: 15394-15399 [Abstract] [Full Text]  
• Lohrengel, S., Hermann, F., Hagmann, I., Oberwinkler, H., Scrivano, L., Hoffmann, C., von Laer, D., Dittmar, M. T. (2005). Determinants of Human Immunodeficiency Virus Type 1 Resistance to Membrane-Anchored gp41-Derived Peptides. J. Virol. 79: 10237-10246 [Abstract] [Full Text]  
• Ceccherini-Silberstein, F., Gago, F., Santoro, M., Gori, C., Svicher, V., Rodriguez-Barrios, F., d'Arrigo, R., Ciccozzi, M., Bertoli, A., Monforte, A. d., Balzarini, J., Antinori, A., Perno, C.-F. (2005). High Sequence Conservation of Human Immunodeficiency Virus Type 1 Reverse Transcriptase under Drug Pressure despite the Continuous Appearance of Mutations. J. Virol. 79: 10718-10729 [Abstract] [Full Text]  
• Stanic, A., Schneider, T. K. (2005). Overview of Antiretroviral Agents in 2005. Journal of Pharmacy Practice 18: 228-246 [Abstract]  
• Rusert, P., Kuster, H., Joos, B., Misselwitz, B., Gujer, C., Leemann, C., Fischer, M., Stiegler, G., Katinger, H., Olson, W. C., Weber, R., Aceto, L., Gunthard, H. F., Trkola, A. (2005). Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors. J. Virol. 79: 8454-8469 [Abstract] [Full Text]  
• Svicher, V., Ceccherini-Silberstein, F., Erba, F., Santoro, M., Gori, C., Bellocchi, M. C., Giannella, S., Trotta, M. P., Monforte, A. d., Antinori, A., Perno, C. F. (2005). Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors. Antimicrob. Agents Chemother. 49: 2015-2025 [Abstract] [Full Text]  
• Zoulim, F. (2005). Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. J Antimicrob Chemother 55: 608-611 [Abstract] [Full Text]  
• Monie, D., Simmons, R. P., Nettles, R. E., Kieffer, T. L., Zhou, Y., Zhang, H., Karmon, S., Ingersoll, R., Chadwick, K., Zhang, H., Margolick, J. B., Quinn, T. C., Ray, S. C., Wind-Rotolo, M., Miller, M., Persaud, D., Siliciano, R. F. (2005). A Novel Assay Allows Genotyping of the Latent Reservoir for Human Immunodeficiency Virus Type 1 in the Resting CD4+ T Cells of Viremic Patients. J. Virol. 79: 5185-5202 [Abstract] [Full Text]  
• Bouchonnet, F., Dam, E., Mammano, F., de Soultrait, V., Hennere, G., Benech, H., Clavel, F., Hance, A. J. (2005). Quantification of the Effects on Viral DNA Synthesis of Reverse Transcriptase Mutations Conferring Human Immunodeficiency Virus Type 1 Resistance to Nucleoside Analogues. J. Virol. 79: 812-822 [Abstract] [Full Text]  
• Herzmann, C., Karcher, H., Goulder, P. J.R., Blanckenberg, N., Dong, K., Lallemant, M., Jourdain, G., Le Coeur, S. (2004). Nevirapine plus Zidovudine to Prevent Mother-to-Child Transmission of HIV. NEJM 351: 2013-2015 [Full Text]  
• Calmy, A., Pascual, F., Ford, N. (2004). HIV Drug Resistance. NEJM 350: 2720-2721 [Full Text]